Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

19.04
+0.80004.39%
Volume:1.03M
Turnover:19.32M
Market Cap:1.91B
PE:-4.16
High:19.28
Open:18.38
Low:18.34
Close:18.24
Loading ...

Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright

TIPRANKS
·
10 Mar

Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target

TIPRANKS
·
10 Mar

Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target

MT Newswires Live
·
10 Mar

Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst

TIPRANKS
·
10 Mar

Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now?

Insider Monkey
·
10 Mar

Beam Therapeutics Says Initial Data Show BEAM-302 Increases Alpha-1 Antitrypsin Protein

MT Newswires Live
·
10 Mar

Beam Therapeutics Prices $500 Million Share, Warrant Offering

MT Newswires Live
·
10 Mar

BUZZ-Beam Therapeutics rises on early-stage trial results for gene editing therapy

Reuters
·
10 Mar

Beam Therapeutics Shares up 10.4% Premarket After Early-Stage Data for Gene Editing Therapy

THOMSON REUTERS
·
10 Mar

BRIEF-Beam Therapeutics Announces Pricing Of Underwritten Offering

Reuters
·
10 Mar

BRIEF-Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels

Reuters
·
10 Mar

Beam Therapeutics: Single Dose of Beam-302 Led to Durable, Dose-Dependent Increases in Total and Functional Alpha-1 Antitrypsin

THOMSON REUTERS
·
10 Mar

Beam Therapeutics: Pricing of Underwritten Offering of 16.2 Mln Shares at Price $28.48 per Share

THOMSON REUTERS
·
10 Mar

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

GlobeNewswire
·
10 Mar

AI Biotech Stocks Shined, With Ginkgo Up 8%, Recursion And Absci Up 4%, Crispr Up 3%

Tiger Newspress
·
05 Mar

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14%

Benzinga
·
05 Mar

Beam Therapeutics Inc : Scotiabank Raises Target Price to $25 From $24

THOMSON REUTERS
·
03 Mar

Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations

TIPRANKS
·
28 Feb

Beam Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
27 Feb

Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates

Zacks
·
26 Feb